For GH-treated patients, reported events of insomnia, dyspnea, anxiety, sleep apnea, and decreased libido were mild to moderate in severity (as reported by the investigator) in 93%, 92%, 82%, 85%, and 90% of patients, respectively, and were reported during the first year of GH treatment in 58%, 61%, 52%, 44%, and 55% of patients, respectively. Here, GH1 is linked to sleep apnea syndrome.